Aperio Group LLC Has $625,000 Position in Meridian Bioscience, Inc. (VIVO)
Aperio Group LLC cut its stake in shares of Meridian Bioscience, Inc. (NASDAQ:VIVO) by 6.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 44,650 shares of the company’s stock after selling 3,252 shares during the period. Aperio Group LLC’s holdings in Meridian Bioscience were worth $625,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP lifted its position in Meridian Bioscience by 4.8% during the third quarter. Dimensional Fund Advisors LP now owns 1,748,848 shares of the company’s stock valued at $25,008,000 after purchasing an additional 80,877 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Meridian Bioscience by 1.0% in the third quarter. Bank of New York Mellon Corp now owns 871,560 shares of the company’s stock valued at $12,463,000 after acquiring an additional 8,377 shares in the last quarter. Northern Trust Corp lifted its position in shares of Meridian Bioscience by 1.6% in the second quarter. Northern Trust Corp now owns 557,398 shares of the company’s stock valued at $8,780,000 after acquiring an additional 8,886 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Meridian Bioscience by 12.4% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 471,456 shares of the company’s stock valued at $6,601,000 after acquiring an additional 51,976 shares in the last quarter. Finally, SG Capital Management LLC purchased a new position in shares of Meridian Bioscience in the third quarter valued at about $5,235,000. Institutional investors own 89.12% of the company’s stock.
Several equities analysts have recently commented on the company. Canaccord Genuity boosted their price objective on Meridian Bioscience from $14.00 to $16.00 and gave the company a “hold” rating in a research report on Friday, January 26th. BidaskClub downgraded Meridian Bioscience from a “hold” rating to a “sell” rating in a research report on Saturday, February 3rd. Finally, Zacks Investment Research downgraded Meridian Bioscience from a “buy” rating to a “hold” rating in a research report on Sunday, January 21st.
Meridian Bioscience (NASDAQ:VIVO) last announced its quarterly earnings data on Thursday, January 25th. The company reported $0.15 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.14 by $0.01. Meridian Bioscience had a return on equity of 17.00% and a net margin of 10.46%. The business had revenue of $52.30 million for the quarter, compared to the consensus estimate of $49.00 million. During the same period in the previous year, the business earned $0.15 earnings per share. The business’s revenue was up 11.8% on a year-over-year basis. sell-side analysts predict that Meridian Bioscience, Inc. will post 0.71 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, February 15th. Stockholders of record on Monday, February 5th were given a $0.125 dividend. The ex-dividend date of this dividend was Friday, February 2nd. This represents a $0.50 annualized dividend and a dividend yield of 3.60%. Meridian Bioscience’s payout ratio is 87.72%.
About Meridian Bioscience
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience, Inc. (NASDAQ:VIVO).
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.